Scarica l'app Stockscreener
65.91
0.24%
0.16
Dopo l'orario di chiusura:
65.68
-0.23
-0.35%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$65.75
Aprire:
$66.31
Volume 24 ore:
3.89M
Relative Volume:
0.60
Capitalizzazione di mercato:
$25.71B
Reddito:
$4.30B
Utile/perdita netta:
$571.50M
Rapporto P/E:
46.14
EPS:
1.4285
Flusso di cassa netto:
$570.80M
1 W Prestazione:
-4.40%
1M Prestazione:
+9.54%
6M Prestazione:
-18.64%
1 anno Prestazione:
-12.42%
Intervallo 1D:
$65.56
$66.67
Intervallo di 1 settimana:
$65.20
$69.31
Portata 52W:
$54.11
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Confronta DXCM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
65.91 | 25.64B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
125.12 | 220.33B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.11 | 140.06B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
353.11 | 134.83B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.48 | 126.02B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.80 | 49.23B | 5.88B | 1.34B | 799.60M | 2.3489 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Iniziato | Evercore ISI | In-line |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
Meme Stocks: What sentiment indicators say about DexCom Inc. stockGap Down & Community Verified Trade Signals - Улправда
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DexCom (DXCM) Fell Due to Modest Guidance - Insider Monkey
Sendero Wealth Management LLC Has $4.54 Million Position in DexCom, Inc. $DXCM - MarketBeat
Thrivent Financial for Lutherans Lowers Holdings in DexCom, Inc. $DXCM - MarketBeat
Assenagon Asset Management S.A. Cuts Stock Position in DexCom, Inc. $DXCM - MarketBeat
DexCom (NASDAQ:DXCM) Given New $78.00 Price Target at Mizuho - Defense World
DexCom, Inc. $DXCM Shares Bought by Gradient Investments LLC - Defense World
Investors who lost money on DexCom, Inc.(DXCM) should - GlobeNewswire
Key facts: Class action lawsuit filed against DexCom; Mizuho raises price target - TradingView — Track All Markets
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now - The Globe and Mail
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
DexCom (DXCM): Mizuho Raises Price Target to $78, Maintains Outp - GuruFocus
DXCM LAWSUIT ALERT: Levi & Korsinsky Notifies DexCom, Inc. InvestorsLead Plaintiff Deadline December 26, 2025 - ACCESS Newswire
Class Action Lawsuit Filed Against DexCom, Inc. (DXCM)Recover LossesContact Levi & Korsinsky Before December 26, 2025 - ACCESS Newswire
DexCom, Inc. Deadline Approaching: Kessler Topaz Meltzer & - GlobeNewswire
DexCom, Inc. Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit - GlobeNewswire Inc.
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Join Class Action to Recover Losses from DexCom, Inc. (DXCM)Contact Levi & Korsinsky Before December 26, 2025 - ACCESS Newswire
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Leerink Partners Adjusts Price Target on DexCom to $92 From $81, Maintains Outperform Rating - marketscreener.com
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of DexCom, Inc. Investors - GlobeNewswire
4 Reasons Why DexCom Could Be A Good Buy For 2026 (NASDAQ:DXCM) - Seeking Alpha
Shareholders of DexCom, Inc. Should Contact Levi & Korsinsky Before December 26, 2025 to Discuss Your RightsDXCM - Sahm
DXCM Deadline: DXCM Investors with Losses in Excess of $100K Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit - Morningstar
DexCom Inc. Stock Underperforms Monday When Compared To Competitors - 富途牛牛
Lost Money on DexCom, Inc.(DXCM)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - GlobeNewswire
Shareholders SueWallSt in New Class Action Against DexCom, Inc.Act Now - Nasdaq
DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class ActionContact Lieff Cabraser - ACCESS Newswire
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Investors in DexCom, Inc. (DXCM): Protect Your RightsContact Levi & Korsinsky Before December 26, 2025 - Stockhouse
DEXCOM, INC. (NASDAQ: DXCM) DEADLINE ALERT Bernstein - GlobeNewswire
Shareholders of DexCom, Inc. (DXCM): Protect Your Rights Before December 26, 2025Contact Levi & Korsinsky - Stockhouse
DXCM CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. Shareholders of Securities Fraud Class Action Lawsuit - PR Newswire
Castleark Management LLC Invests $27.18 Million in DexCom, Inc. $DXCM - MarketBeat
2025-12-13 | Levi & Korsinsky Notifies DexCom, Inc. (DXCM) Shareholders of Class Action Lawsuit and December 26, 2025 Deadline | NDAQ:DXCM | Press Release - Stockhouse
Jim Cramer on DexCom: "It's Too Rich a Stock" - Finviz
Jim Cramer on DexCom: “It’s too rich a stock” - MSN
Jim Cramer on DexCom: “It’s Too Rich a Stock” - Insider Monkey
Bellevue Group AG Cuts Holdings in DexCom, Inc. $DXCM - MarketBeat
Shareholders of DexCom, Inc. Should Contact Levi & - GlobeNewswire
Key facts: DexCom faces class action lawsuit; Citigroup raises price target - TradingView — Track All Markets
DexCom, Inc. Investors Reminder: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. Shareholders of Deadline in Securities Fraud Class Action Lawsuit - Business Wire
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SueWallSt Podcast Explains Class Action Against DexCom, Inc. (DXCM) - ACCESS Newswire
Holzer & Holzer, LLC Reminds Investors of Upcoming Lead - GlobeNewswire
Citigroup Maintains DexCom (DXCM) Buy Recommendation - Nasdaq
DexCom Stock Surges 12%, With A 11-Day Winning Spree - Trefis
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
0.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):